Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Lei M, Overman MJ, Yao J, André T, Lonardi S, Lenz HJ, Aglietta M, Gelsomino F, McDermott R, Wong KYM, Morse MA, Van Cutsem E, Hendlisz A, Cardin DB, Neyns B, Hill A, Krishnamurthy A, Chen F, Kochuparambil S, Jenq RR, Abdullaev S, He B, Novosiadly R, Kopetz S